Syros Pharmaceuticals Inc. (NASDAQ: SYRS) is -33.46% lower on its value in year-to-date trading and has touched a low of $6.03 and a high of $15.65 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SYRS stock was last observed hovering at around $7.48 in the last trading session, with the day’s loss setting it -0.26% off its average median price target of $16.00 for the next 12 months. It is also 63.9% off the consensus price target high of $20.00 offered by 8 analysts, but current levels are 44.46% higher than the price target low of $13.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $7.22, the stock is -14.01% and -26.26% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.58 million and changing -3.48% at the moment leaves the stock -29.69% off its SMA200. SYRS registered 18.36% gain for a year compared to 6-month loss of -11.74%. The firm has a 50-day simple moving average (SMA 50) of $8.95 and a 200-day simple moving average (SMA200) of $9.70.
The stock witnessed a -9.07% gain in the last 1 month and extending the period to 3 months gives it a -32.71%, and is -2.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.25% over the week and 9.45% over the month.
Syros Pharmaceuticals Inc. (SYRS) has around 103 employees, a market worth around $450.82M and $15.10M in sales. Distance from 52-week low is 19.73% and -53.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.90%).
Syros Pharmaceuticals Inc. (SYRS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Syros Pharmaceuticals Inc. (SYRS) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.90, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Syros Pharmaceuticals Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.46 with sales reaching $2.67M over the same period.The EPS is expected to grow by 2.70% this year, but quarterly earnings will post -18.90% year-over-year.
Syros Pharmaceuticals Inc. (SYRS) Top Institutional Holders
139 institutions hold shares in Syros Pharmaceuticals Inc. (SYRS), with 3.02M shares held by insiders accounting for 4.90% while institutional investors hold 89.77% of the company’s shares. The shares outstanding are 61.64M, and float is at 56.72M with Short Float at 8.60%. Institutions hold 85.37% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 9.04 million shares valued at $98.1 million. The investor’s holdings represent 14.67% of the SYRS Shares outstanding. As of Dec 30, 2020, the second largest holder is FMR, LLC with 6.64 million shares valued at $72.05 million to account for 10.77% of the shares outstanding. The other top investors are Bain Capital Life Sciences Investors, LLC which holds 5.79 million shares representing 9.39% and valued at over $62.77 million, while Nikko Asset Management Americas, Inc. holds 7.11% of the shares totaling 4.38 million with a market value of $47.54 million.
Syros Pharmaceuticals Inc. (SYRS) Insider Activity
A total of 14 insider transactions have happened at Syros Pharmaceuticals Inc. (SYRS) in the last six months, with sales accounting for 9 and purchases happening 5 times. The most recent transaction is an insider sale by Olson Eric R ,the company’sChief Scientific Officer. SEC filings show that Olson Eric R sold 3,628 shares of the company’s common stock on Mar 15 at a price of $9.47 per share for a total of $34372.0. Following the sale, the insider now owns 0.0 shares.
Syros Pharmaceuticals Inc. disclosed in a document filed with the SEC on Feb 16 that Young Richard A (Director) sold a total of 3,750 shares of the company’s common stock. The trade occurred on Feb 16 and was made at $12.05 per share for $45188.0. Following the transaction, the insider now directly holds 0.32 million shares of the SYRS stock.
Still, SEC filings show that on Feb 08, Young Richard A (Director) disposed off 3,750 shares at an average price of $13.04 for $48900.0. The insider now directly holds 325,461 shares of Syros Pharmaceuticals Inc. (SYRS).
Syros Pharmaceuticals Inc. (SYRS): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading 25.36% up over the past 12 months. Short interest in the company’s stock has risen 25.41% from the last report on Feb 11, 2021 to stand at a total of 3.64 million short shares sold with a short interest ratio of 6.27.